The goal is ambitious. Germany is to become one of the world's most attractive locations for biotechnology. This is based on the realisation that the technology is far more than just a tool for medicine. It is increasingly recognised as a key industry for health, nutrition, agriculture and industrial value creation. The Federal Government has formulated concrete milestones, particularly in the health sector. The first individualised mRNA cancer immunotherapy is to be approved by 2028. At the same time, a new centre for gene and cell therapies is being established in Berlin, which will be funded with up to 100 million euros and offer space for numerous start-ups. The aim is to translate research into marketable therapies more quickly and close the gap between the laboratory and patient care. The roadmap thus follows a global trend. Biology, data science and artificial intelligence are increasingly merging to form a new innovation platform. New drugs can be developed faster, diseases can be diagnosed more precisely and therapies can be customised. In this race, Germany no longer wants to limit itself to its role as a centre of research, but also wants to build up industrial value creation in its own country. This is an important signal for the industry. After years of intensive research, biotechnology should not only deliver scientific breakthroughs in future, but also create new companies, jobs and growth. This will make life sciences a central component of German innovation and economic policy.
Online consultation: https://d486.keyingress.de/?i_survey=50__51fc98fa6391610039593cfa83247263
Press release from the "Federal Ministry of Research, Technology and Space" dated 20 May 2026